HDAC inhibitor-based therapies: can we interpret the code? by New, M, Olzscha, H, La Thangue, N

The TLR adaptor protein MyD88 mediates cell sensitivity to HDAC inhibitors through a cytokine-dependent mechanism by Sheikh, S, New, M, Bekheet, M, Olzscha, H, La Thangue, N

CBP/p300 bromodomains regulate amyloid-like protein aggregation upon aberrant lysine acetylation by Olzscha, H, Fedorov, O, Kessler, B, Knapp, S, La Thangue, N

Bromodomains control amyloid-like aggregation of aberrantly acetylated proteins by Olzscha, H, Fedorov, O, Kessler, B, Knapp, S, La Thangue, N

TLR adaptor protein MYD88 mediates sensitivity to HDAC inhibitors via a cytokine-dependent mechanism by New, M, Sheikh, S, Bekheet, M, Olzscha, H, Thezenas, M, Care, M, Fotheringham, S, Tooze, R, Kessler, B, La Thangue, N

A regulatory circuit that involves HR23B and HDAC6 governs the biological response to HDAC inhibitors. by New, M, Olzscha, H, Liu, G, Khan, O, Stimson, L, McGouran, J, Kerr, D, Coutts, A, Kessler, B, Middleton, M, La Thangue, N

A regulatory circuit that involves HR23B and HDAC6 governs the biological response to HDAC inhibitors by New, M, Olzscha, H, Liu, G, Khan, O, Stimson, L, McGouran, J, Coutts, A, Kessler, B, La Thangue, N, Kerr, D, Middleton, M

Generation of a Selective Small Molecule Inhibitor of the CBP/p300 Bromodomain for Leukemia Therapy by Picaud, S, Fedorov, O, Thanasopoulou, A, Leonards, K, Jones, K, Meier, J, Olzscha, H, Monteiro, O, Martin, S, Philpott, M, Tumber, A, Filippakopoulos, P, Yapp, C, Wells, C, Che, K, Bannister, A, Robson, S, Kumar, U, Parr, N, Lee, K, Lugo, D, Jeffrey, P, Taylor, S, Vecellio, M, Bountra, C, Brennan, P, O'Mahony, A, Velichko, S, Müller, S, Hay, D, Daniels, D, Urh, M, La Thangue, N, Kouzarides, T, Prinjha, R, Schwaller, J, Knapp, S